Scientists try to 'Wake Up' cancer target to boost therapy
NCT ID NCT05178693
Summary
This early-stage study is testing a new approach for patients with advanced neuroendocrine tumors that have spread. The goal is to see if taking a pill (ASTX727) for five days can 'switch on' a specific target on the cancer cells, making a follow-up radioactive therapy (Lutathera) more effective. Researchers will use special scans to check if the target is reactivated and monitor how patients respond to the combined treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hammersmith Hospital
RECRUITINGLondon, London, City of, W12 0HS, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.